The antithrombotic effect of the aminoestrogen prolame (N-(3-hydroxy-1,3,5(10)-estratrien-17B-YL)-3-hydroxypropylamine) is linked to an increase in nitric oxide production by platelets and endothelial cells

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 62-68

  González, Georgina ^a   Alvarado Vasquez, Noé ^b   Fernández G, Juan Manuel ^d   Cruz Robles, David ^c   del Valle, Leonardo ^c   Pinzón, Enrique ^a   Torres, Ismael ^a   Rodriguez, Emma ^c   Zapata, Estrella ^c   Gómez Vidales, Virginia ^d   Montaño, Luis Felipe ^a   de la Peña, Aurora ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Aminoestrogen; Endothelial cells; Nitric oxide; Prolame; Thrombosis

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR; MESSENGER RNA; NITRIC OXIDE; PROLAME;

ADULT ANIMAL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; ELECTRON SPIN RESONANCE; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBUS;

EID: 73649121679     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.017     Document Type: Article

References (31)

1. Bakir S., Mori T., Durand J., Chen Y.F., Thompson J.A., and Oparil S. Circulation 101 (2000) 2342-2344
2. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA 280 (1998) 605-613
3. Anderson G.L., Limacher M., Assaf A.R., et al. Women's health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's health initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
4. Kelemen M., Vaidya D., Waters D.D., et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the women's angiographic vitamin and estrogen (WAVE) trial. Atherosclerosis 179 (2005) 193-200
5. Steiner A.Z., Xiang M., Mack W.J., et al. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. Obstet Gynecol 109 (2007) 581-587
6. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
7. Vickers M.R., MacLennan A.H., Lawton B., et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335 (2007) 239-244
8. Mandoki J.J., Zavala E., Silva G., et al. Proc West Pharmacol Soc 26 (1983) 45-48
9. Rosendaal F.R., Van Hylckama Vlieg A., Tanis B.C., and Helmerhorst F.M. Estrogens, progestogens and thrombosis. J Thromb Haemost 1 (2003) 1371-1380
10. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344 (2001) 1527-1535
11. Fernández-G. J.M., Rubio-Arroyo M.F., Soriano-García M., et al. Synthesis and molecular structure of prolame, N(-3-hydroxy-1,3,5(10)estratrien-17β-yl)-3-hydroxypropylamine. An amino-estrogen with prolonged anticoagulant and brief estrogenic effects. Steroids 45 (1985) 151-157
12. Lemini C., Franco Y., Avila E., and Jaimez R. Contrasting effects of estradiol and 17 beta-aminoestrogens on blood clotting time in rats and mice. Eur J Pharm 510 (2005) 229-233
13. Rubio-Poo C., Mandoki J.J., Mendoza-Patiño N., et al. The anticoagulant effect of prolame, N-(3-hydroxy-1,3,5(10)estratrien-17β-yl)-3-hydroxypropylamine, a novel amino-estrogen. Steroids 45 (1985) 159-170
14. de la Peña A., Baños G., Izaguirre R., Mandoki J.J., and Fernández-G. J.M. Comparative effect of synthetic amino-estrogens with estradiol on platelet aggregation. Steroids 58 (1993) 407-409
15. Jaimez R., Cooney A., Jackson K., et al. In vivo estrogen bioactivities and in vitro estrogen receptor binding and transcriptional activities of anticoagulant synthetic 17beta-aminoestrogens. J Steroid Biochem Mol Biol 73 (2000) 59-66
16. García-Manzano A., González-Llaven J., Jaimez R., et al. Changes on hemostatic parameters induced by 17beta-estradiol, ethinylestradiol, and the 17beta-aminoestrogen pentolame in the male Wistar rat. Steroids 67 (2002) 1129-1135
17. Ades E.W., Candal F.J., Swerlick R.A., et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99 (1992) 683-690
18. Freshney R.I. Culture of animal cells. A manual of basic technique. 3rd ed. (1993), Wiley-Liss, New York
19. Marcus A.J., Safier L.B., Hajjar K.A., et al. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. J Clin Invest 88 (1991) 1690-1696
20. Tenorio F.A., del Valle L., and Pastelin G. Validación de un método espectrofotométrico para la cuantificación de metabolitos de NO en fluidos biológicos. Rev Mexicana de Ciencias Farmacéuticas 36 (2005) 31-40
21. Day S.M., Reeve J.L., Myers D.D., and Fay W.P. Murine thrombosis models. Thromb Haemost 92 (2004) 486-494
22. Tsuchiya K., Kirima K., Yoshizumi M., and Tamaki T. New methods to evaluate endothelial function: evaluation of endothelial function by hemoglobin-nitric oxide complex using electron paramagnetic resonance spectroscopy. J Pharmacol Sci 93 (2003) 417-422
23. Ferreiro C.R., Chagas A.C., Carvalho M.H., et al. Expression of inducible nitric oxide synthase is increased in patients with heart failure due to ischemic disease. Braz J Med Biol Res 37 (2004) 1313-1320
24. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., and Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100 (1997) 350-356
25. Marjanovic J.A., Li Z., Stojanovic A., and Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem 280 (2005) 37430-37438
26. Naseem K.M., and Riba R. Unresolved roles of platelet nitric oxide synthase. J Thromb Haemost 6 (2008) 10-19
27. Guetta V., Quyyumi A.A., Prasad A., Panza J.A., Waclawiw M., and Cannon III R.O. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 96 (1997) 2795-2801
28. Hayashi T., Yamada K., Esaki T., et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 214 (1995) 847-855
29. Miyazaki-Akita A., Hayashi T., Ding Q.F., et al. 17beta-estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose: relevance to postmenopausal diabetic cardiovascular disease. J Pharmacol Exp Ther 320 (2007) 591-598
30. Serock M.R., Wells A.K., and Khalil R.A. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov 3 (2008) 165-186
31. Russell K.S., Haynes M.P., Sinha D., Clerisme E., and Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 97 (2000) 5930-5935